Keep in touch

Target Medicines

PriorityARVs_webcover New December 2013 Working Paper:
ARV Priority List for the Medicines Patent Pool Priority Antiretrovirals for the Medicines Patent Pool – Third Edition
Comments welcome and encouraged. Please mail input to gro.looptnetapsenicidemnull@eciffo with subject line “Comments on ARV Priority List Working Paper”

The Medicines Patent Pool focuses on increasing access to HIV medicines. Target medicines include those that exist but are either too expensive because of a lack of competition or are not adapted to the specific needs of resource-limited settings (e.g. medicines for children). They also include those that exist, but for which fixed-dose combinations have not yet been developed, drugs that are not yet available on the market, or those that are still under development.

The HIV medicines currently targeted for inclusion in the Medicines Patent Pool are chosen based on ongoing consultation with a wide variety of HIV experts. A working paper explaining the rationale for choosing these medicines is available here. The working paper is a living document currently in its third edition. Comments are both welcome and encouraged.
The second edition was released in November 2012, and is available here [pdf]; the first edition was released September 2011 and is available here [pdf].

Work is constantly on-going to revise the list of priority products for inclusion in the Medicines Patent Pool, as the field for HIV medicines changes constantly and new products are being developed and as more information is gathered about what is patented and where. The priority list will be updated on the basis of the latest scientific knowledge.

Current target products and formulations:

The MPP decides on target medicines based on two criteria: the medicine’s clinical importance (determined with the aid of medical and public health experts) and the existence of market and/or patent barriers that might prevent access to it. Each drug gets a ranking within each criterion of high, medium, or low.


Compound Clinical Priority Market/IP Priority Main Patent Holder

Atazanavir (ATV)*

High High Bristol-Myers Squibb

Dolutegravir (DLG)*

High High ViiV Healthcare

Lopinavir (LPV)*

High High AbbVie

Ritonavir (RTV or r)*

High High AbbVie

Tenofovir Alafenamide Fumarate (TAF)*

High High Gilead Sciences

Cobicistat (COBI)*

High High Gilead Sciences

Elvitegravir (EVG)*

High High Gilead Sciences

Abacavir (ABC) (paediatrics)*°

High Medium ViiV Healthcare

Emtricitabine (FTC)*

High Medium Gilead Sciences

Efavirenz (EFV)

High Medium Merck & Co

Tenofovir Disoproxil Fumarate (TDF)*

High Medium Gilead Sciences

Darunavir (DRV)*°°

Medium/High Medium Johnson & Johnson/Tibotec

Nevirapine (NVP)**

Medium/High Medium Boehringer-Ingelheim

Etravirine (ETV)

Medium High Johnson & Johnson/Tibotec

Raltegravir (RAL)*

Medium High Merck Sharp & Dohme (MSD)

Rilpivirine (RPV)

Medium High Johnson & Johnson/Tibotec

*    ARVs already licensed to the Medicines Patent Pool
**  ARVs for which the Medicines Patent Pool is in negotiations.
*** ARVs for which the Mediciens Patent Pool is in negotiations for paediatric formulations.
°    Abacavir is identified as a priority for paediatrics in current treatment recommendations, but may become important for adult treatment in the future in the context of ongoing clinical trials with ABC/3TC/DTG.
°°   MPP has concluded a licence agreement for patents related to Darunavir with the US National Institute of Health, but additional licences are needed to allow for generic manufacture.


The table above is based on the MPP’s ARV Priority List [pdf]. Earlier proposed lists of priority essential medicines for HIV as developed by UNITAID and the WHO are listed in “The Selection and Use of Essential Medicines.” More information on the list of priority missing essential medicines for HIV developed by UNITAID and the WHO, please read “UNITAID and WHO Secretariat proposal: the priority missing essential medicines for HIV.”

The Medicines Patent Pool on 18 February 2011 submitted a joint document with UNITAID and the WHO HIV/AIDS Department to the WHO Expert Committee on the Selection and Use of Essential Medicines. This document, available here [pdf], revises the list of missing antiretroviral formulations needed to treat adults and children living with HIV. It was reviewed at the 21-25 March meeting of the Expert Committee, and the evidence was incorporated into the ARV Priority List released in September 2011.

This page is also available in: French, Spanish